BR0308431A - Parecoxib sódico cristalino - Google Patents

Parecoxib sódico cristalino

Info

Publication number
BR0308431A
BR0308431A BR0308431-0A BR0308431A BR0308431A BR 0308431 A BR0308431 A BR 0308431A BR 0308431 A BR0308431 A BR 0308431A BR 0308431 A BR0308431 A BR 0308431A
Authority
BR
Brazil
Prior art keywords
parecoxib
unsolvated
slurry
crystalline
parecoxib sodium
Prior art date
Application number
BR0308431-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Ahmad Y Sheikh
Thomas R Borchardt
Leonard J Ferro
Gerald D Danzer
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BR0308431A publication Critical patent/BR0308431A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
BR0308431-0A 2002-03-15 2003-03-12 Parecoxib sódico cristalino BR0308431A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36456702P 2002-03-15 2002-03-15
US41798702P 2002-10-11 2002-10-11
PCT/US2003/007484 WO2003078408A1 (en) 2002-03-15 2003-03-12 Crystalline parecoxib sodium

Publications (1)

Publication Number Publication Date
BR0308431A true BR0308431A (pt) 2005-01-18

Family

ID=28045416

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308431-0A BR0308431A (pt) 2002-03-15 2003-03-12 Parecoxib sódico cristalino

Country Status (18)

Country Link
US (1) US20030232871A1 (enExample)
EP (1) EP1485362A1 (enExample)
JP (1) JP2005529084A (enExample)
KR (1) KR100763045B1 (enExample)
CN (1) CN1642926A (enExample)
AR (1) AR038985A1 (enExample)
AU (1) AU2003220180A1 (enExample)
BR (1) BR0308431A (enExample)
CA (1) CA2478500A1 (enExample)
CO (1) CO5631437A2 (enExample)
IL (1) IL163780A0 (enExample)
MX (1) MXPA04008932A (enExample)
MY (1) MY148518A (enExample)
NZ (1) NZ535951A (enExample)
PL (1) PL372880A1 (enExample)
RU (1) RU2300529C2 (enExample)
TW (1) TW200400949A (enExample)
WO (1) WO2003078408A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087682A1 (en) * 2003-04-04 2004-10-14 Hetero Drugs Limited Novel crystalline forms of parecoxib sodium
CA2540895C (en) 2003-10-02 2016-08-02 Elan Pharmaceuticals, Inc. Combinations of ziconotide and opioids for reducing pain
CA2551523A1 (en) * 2003-12-24 2005-07-21 Pharmacia Corporation Metal salts of parecoxib as prodrugs of the cox-2 inhibitor valdecoxib for the treatment of inflammation, pain and/or fever
ITMI20040019A1 (it) * 2004-01-12 2004-04-12 Univ Bari Derivati isossazolici e loro impiego come inibitori della ciclossigenasi
US7796785B2 (en) * 2005-03-03 2010-09-14 Fujifilm Corporation Image extracting apparatus, image extracting method, and image extracting program
US20080108664A1 (en) 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
US7989450B2 (en) 2008-01-11 2011-08-02 Universita' Degli Studi Di Bari Functionalized diarylisoxazoles inhibitors of ciclooxygenase
GB0919757D0 (en) * 2009-11-12 2009-12-30 Johnson Matthey Plc Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
US8299295B2 (en) * 2009-10-15 2012-10-30 Johnson Matthey Public Limited Company Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
CN105726496B (zh) * 2014-12-12 2019-05-28 湖南科伦药物研究有限公司 一种帕瑞昔布钠冻干粉剂、其制备方法及其粉剂产品
CN105125506A (zh) * 2015-08-18 2015-12-09 上海秀新臣邦医药科技有限公司 一种注射用帕瑞昔布钠及其制备方法
CN106580893A (zh) * 2016-12-26 2017-04-26 上药东英(江苏)药业有限公司 一种帕瑞昔布钠冻干粉针制剂
CN106692079A (zh) * 2016-12-26 2017-05-24 上药东英(江苏)药业有限公司 一种帕瑞昔布钠长效冻干粉针制剂
CN117003769B (zh) * 2023-07-11 2024-11-22 中国科学院宁波材料技术与工程研究所 氯诺昔康复合物、氯诺昔康-小檗碱共晶及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20032998B (en) * 1996-04-12 2003-06-25 Searle & Co Substituted Benzenesulfonamide Derivatives as Prodrugs of Cox-2 Inhibitors
ATE271385T1 (de) * 1996-10-15 2004-08-15 Searle Llc Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia
PE20021017A1 (es) * 2001-04-03 2002-11-24 Pharmacia Corp Composicion parenteral reconstituible
US20030105334A1 (en) * 2001-10-02 2003-06-05 Letendre Leo J. Method for preparing benzenesulfonyl compounds

Also Published As

Publication number Publication date
IL163780A0 (en) 2005-12-18
TW200400949A (en) 2004-01-16
MY148518A (en) 2013-04-30
KR20040095288A (ko) 2004-11-12
KR100763045B1 (ko) 2007-10-04
MXPA04008932A (es) 2004-11-26
JP2005529084A (ja) 2005-09-29
CA2478500A1 (en) 2003-09-25
NZ535951A (en) 2006-02-24
CN1642926A (zh) 2005-07-20
RU2300529C2 (ru) 2007-06-10
RU2004127585A (ru) 2005-04-10
PL372880A1 (en) 2005-08-08
US20030232871A1 (en) 2003-12-18
AR038985A1 (es) 2005-02-02
EP1485362A1 (en) 2004-12-15
AU2003220180A1 (en) 2003-09-29
CO5631437A2 (es) 2006-04-28
WO2003078408A1 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
AR014886A1 (es) 4,5-diarilimidazoles 2-substituidos, composiciones farmaceuticas que los contienen y su uso para la manufactura de medicamentos
NO20081593L (no) Depotsammensetning
ECSP067076A (es) Derivados de pirimidina urea como inhibidores de la quinasa
HN2005000484A (es) Nuevas composiciones farmaceuticas para el tratamiento de trastornos hiperproliferativos
MX2021006265A (es) Derivados de panteteina y usos de los mismos.
ES2173948T3 (es) Mezclas de 2',3'-didesoxi-inosina e hidrocarbamida para la inhibicion de la propagacion retroviral.
SG151254A1 (en) Substituted morpholine and thiomorpholine derivatives
AR045937A1 (es) Modulacion de la expresion del factor de iniciacion eucariotico eif4e
AR082825A2 (es) Inhibidores heterociclicos nitrogenados de mek, composiciones farmaceuticas que los contienen, metodos para prepararlos y uso de los mismos para el tratamiento de trastornos hiperproliferativos o inflamatorios
BR0317463A (pt) Métodos de triar para um composto que evita ou reduz a dissolução de um tetrâmero de transtiretina e de tratar uma doença amilóide transtiretina
TW200626558A (en) Indazolone derivatives
AR022076A1 (es) Composicion antioxidante constituida por acetil l-carnitina y acido alfa-lipoico para mejorar el aprovechamiento metabolico de la glucosa
DK1697371T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
MXPA03005464A (es) Agentes antivirales.
ITBO20110012A1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
NO20022201L (no) Lösninger inneholdende Epinastin
UY27852A1 (es) Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
CO2019010029A2 (es) Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cáncer
MY141972A (en) Biaryloxymethylarenecarboxylic acids
MY148518A (en) Crystalline parecoxib sodium
BR9908301A (pt) Derivados de indol e composições farmacêuticas que compreendem os mesmos
BRPI0612840A8 (pt) Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções
NO20021160L (no) Bestanddeler
BRPI0508392A (pt) materiais e métodos para tratar distúrbios de coagulação
ES2083708T3 (es) Nuevas piperazinilalcoil-3 dihidro-2,3,4h-benzoxazina-1,3 onas-4 sustituidas, su preparacion y su aplicacion en terapeutica.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A,8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 7A, 8A E 9A ANUIDADES.